Amazing Meds
FDA issued a warning letter to Amazing Meds (Colorado Springs, CO) in September 2025 after reviewing their website and finding they were selling compounded retatrutide and semaglutide products unlawfully. The compounded retatrutide products were cited as unapproved new drugs and misbranded drugs because retatrutide does not appear on the 503A or 503B bulks lists and is not a component of any FDA-approved drug. Additionally, Amazing Meds' claim that their compounded semaglutide is the 'same as Ozempic/Wegovy' was found to be false or misleading, rendering those products misbranded under FDCA sections 502(a) and 502(bb). FDA demanded a written corrective response within 15 working days and warned that failure to comply could result in seizure or injunction.
Flagged claims (1)
Compounded semaglutide (same as Ozempic/Wegovy)
Required actions (3)
You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product).
Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)'s Office of Compliance describing the specific steps you have taken to address any violations.
Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.
Does your site contain similar claims?
The free site audit scans your whole site against every entry in this Atlas. Most pharmacy / compounding sites match 3-6 patterns.
Run my free site auditWorried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.
Check specific copy in the Claim Checker